News
Sarepta may not survive its current gene therapy crisis
Digest more
Sarepta rebuffed a call from the Food and Drug Administration to halt all shipments of its gene therapy for Duchenne muscular ...
Most investors don’t see the drugmaker’s executive management as credible, following the failure to disclose a patient death, ...
On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback